ALKS

SEC source: 0001127602-20-030576 · form4.xml · derivative · entry 2

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,578

Underlying: Ordinary Shares · 5,578 shares

Expires not disclosed

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021.

SEC source: 0001127602-20-030576 · form4.xml · derivative · entry 1

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,509

Underlying: Ordinary Shares · 11,509 shares

Expires 2030-12-02

F1 · derivative.exercise_date: This option becomes exercisable in full on 12/2/2021.

SEC source: 0001127602-20-030570 · form4.xml · derivative · entry 2

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,578

Underlying: Ordinary Shares · 5,578 shares

Expires not disclosed

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021.

SEC source: 0001127602-20-030570 · form4.xml · derivative · entry 1

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,509

Underlying: Ordinary Shares · 11,509 shares

Expires 2030-12-02

F1 · derivative.exercise_date: This option becomes exercisable in full on 12/2/2021.

SEC source: 0001127602-20-026295 · form4.xml · derivative · entry 4

MITCHELL PAUL J · CIK 0001236454 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 20,000 shares

Expires 2020-10-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/6/2019.

F5 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-20-026295 · form4.xml · nonDerivative · entry 2

MITCHELL PAUL J · CIK 0001236454 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Paul J. Mitchell Trust

Disclosed balance after: 7,000

F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/6/2019.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.48 to $16.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F2 · ownership.nature: The reporting person and his wife are co-trustees of The Paul J. Mitchell Trust and the reporting person is also a beneficiary of The Paul J. Mitchell Trust originally established on November 19, 2014 and amended and restated on September 8, 2017 ("The Paul J. Mitchell Trust").

SEC source: 0001127602-20-026295 · form4.xml · nonDerivative · entry 1

MITCHELL PAUL J · CIK 0001236454 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Paul J. Mitchell Trust

Disclosed balance after: 27,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/6/2019.

F2 · ownership.nature: The reporting person and his wife are co-trustees of The Paul J. Mitchell Trust and the reporting person is also a beneficiary of The Paul J. Mitchell Trust originally established on November 19, 2014 and amended and restated on September 8, 2017 ("The Paul J. Mitchell Trust").

SEC source: 0001127602-20-026590 · form4.xml · derivative · entry 3

ANSTICE DAVID W · CIK 0001181171 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 20,000 shares

Expires 2020-10-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: Late filing due to technical error.

F2 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-20-026590 · form4.xml · nonDerivative · entry 2

ANSTICE DAVID W · CIK 0001181171 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,381

F1 · date: Late filing due to technical error.

F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover the option exercise price and related fees.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.72 to $16.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-026590 · form4.xml · nonDerivative · entry 1

ANSTICE DAVID W · CIK 0001181171 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,213

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: Late filing due to technical error.

F2 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001127602-20-021571 · form4.xml · derivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,477

Underlying: Ordinary Shares · 5,523 shares

Expires 2021-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-20-021571 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-019127 · form4.xml · derivative · entry 3

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Ordinary Shares · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 6/7/18.

F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 6/7/18.

SEC source: 0001127602-20-019127 · form4.xml · nonDerivative · entry 2

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,833

SEC source: 0001127602-20-019127 · form4.xml · nonDerivative · entry 1

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,201

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-019126 · form4.xml · derivative · entry 3

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Ordinary Shares · 3,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 6/5/2020.

F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 6/5/2020.

SEC source: 0001127602-20-019126 · form4.xml · nonDerivative · entry 2

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,471

SEC source: 0001127602-20-019126 · form4.xml · nonDerivative · entry 1

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-019123 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · SVP, CLO, Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,934

SEC source: 0001127602-20-017757 · form4.xml · derivative · entry 2

ANSTICE DAVID W · CIK 0001181171 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017757 · form4.xml · derivative · entry 1

ANSTICE DAVID W · CIK 0001181171 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-017777 · form4.xml · derivative · entry 2

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017777 · form4.xml · derivative · entry 1

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-017779 · form4.xml · derivative · entry 2

Wysenski Nancy · CIK 0001294596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017779 · form4.xml · derivative · entry 1

Wysenski Nancy · CIK 0001294596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-017760 · form4.xml · derivative · entry 2

BREYER ROBERT A · CIK 0001236441 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017760 · form4.xml · derivative · entry 1

BREYER ROBERT A · CIK 0001236441 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-017773 · form4.xml · derivative · entry 2

MITCHELL PAUL J · CIK 0001236454 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017773 · form4.xml · derivative · entry 1

MITCHELL PAUL J · CIK 0001236454 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-017767 · form4.xml · derivative · entry 2

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017767 · form4.xml · derivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-017769 · form4.xml · derivative · entry 2

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017769 · form4.xml · derivative · entry 1

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-017776 · form4.xml · derivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017776 · form4.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-017762 · form4.xml · derivative · entry 2

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021.

SEC source: 0001127602-20-017762 · form4.xml · derivative · entry 1

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,823

Underlying: Ordinary Shares · 12,823 shares

Expires 2030-05-20

F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic.

F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021.

SEC source: 0001127602-20-016620 · form4.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 75,000 shares

Expires 2020-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/1/19.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-20-016620 · form4.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 759,094

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/1/19.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.79 to $15.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-016620 · form4.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 834,094

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/1/19.

SEC source: 0001127602-20-016615 · form4.xml · derivative · entry 5

FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 21,983 shares

Expires 2020-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-20-016615 · form4.xml · nonDerivative · entry 1

FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,828

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-016610 · form4.xml · derivative · entry 3

Brown Iain Michael · CIK 0001643456 · SVP Finance & CAO, Alks Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,250 shares

Expires 2020-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/13/2020.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-20-016610 · form4.xml · nonDerivative · entry 2

Brown Iain Michael · CIK 0001643456 · SVP Finance & CAO, Alks Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,581

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/13/2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.15 to $15.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-016610 · form4.xml · nonDerivative · entry 1

Brown Iain Michael · CIK 0001643456 · SVP Finance & CAO, Alks Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,831

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/13/2020.

SEC source: 0001127602-20-016609 · form4.xml · derivative · entry 3

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 18,000 shares

Expires 2020-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/1/2019.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-20-016609 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,822

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/1/2019.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.56 to $15.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-016609 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/1/2019.

SEC source: 0001127602-20-015769 · form4.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Ordinary Shares · 50,000 shares

Expires 2020-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/1/19.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-20-015769 · form4.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 759,094

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/1/19.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.34 to $14.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.